Journal of Medicinal Chemistry p. 6734 - 6750 (2019)
Update date:2022-08-15
Topics:
Wang, Qinghui
Arnst, Kinsie E.
Wang, Yuxi
Kumar, Gyanendra
Ma, Dejian
White, Stephen W.
Miller, Duane D.
Li, Wei
Li, Weimin
ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. Guided by the crystal structure of ABI-231 in complex with tubulin, we performed structure-activity relationship studies around the 3-indole moiety that led to the discovery of several potent ABI-231 analogues, most notably 10ab and 10bb. The crystal structures of 10ab and 10bb in complex with tubulin confirmed their improved molecular interactions to the colchicine site. In vitro, biological studies showed that new ABI-231 analogues disrupt tubulin polymerization, promote microtubule fragmentation, and inhibit cancer cell migration. In vivo, analogue 10bb not only significantly inhibits primary tumor growth and decreases tumor metastasis in melanoma xenograft models but also shows a significant ability to overcome paclitaxel resistance in a taxane-resistant PC-3/TxR model. In addition, pharmacological screening suggested that 10bb has a low risk of potential off-target function.
View MoreJiaxing Taixin Pharmaceutical Chemical Co., Ltd
Contact:0573-82613601
Address:Chemical Park, Jiaxing, Zhejiang, China
Springchem New Material Technology Co.,Limited
website:http://www.spring-chem.com
Contact:86-21-62885108
Address:602B, Building 1, No. 641, Tianshan Road
website:http://www.debyesci.com
Contact:+85221376140
Address:Rm. 19C, Lockhart Ctr., 301-307 Lockhart Rd., Wan Chai
Anhui Eapearl Chemical Co., Ltd.
Contact:86-562-5858458
Address:358 South Huaihe Road
Xi'an yuanfar international trade company
website:https://www.yuanfarchemical.com
Contact:86-029-88745613 ext 828
Address:Floor19th ,B Building, Oak Block,No.36 South Fenghui Road, Dev. Zone of High-Tech Ind.,Xi’an, China
Doi:10.1021/jo970882t
(1997)Doi:10.1021/jo9711495
(1997)Doi:10.1016/S0020-1693(00)81368-7
(1986)Doi:10.1016/S0040-4039(97)01588-8
(1997)Doi:10.1021/jo001323g
(2001)Doi:10.1002/jhet.5570340418
(1997)